CAMBIUM BIO LIMITED — Capital/Financing Update 2021

Oct 13, 2021

==> picture [159 x 33] intentionally omitted <==

14 October 2021

Company Announcements Office Australian Securities Exchange 20 Bridge Street

Sydney NSW 2000

Notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth)

On 14 October 2021, Regeneus Ltd (the " Company ") issued 2,898,551 fully paid ordinary shares in accordance with the terms of its Subscription Agreement with New Life Sciences Capital, LLC, which was announced to the market on 7[th] May 2021.

Accordingly the Company gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Corporations Act ) that:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act ;

2. as at the date of this notice the Company has complied with:

   • (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   • (b) section 674 of the Corporations Act ; and

3. as at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) of the Corporations Act ) which is required to be disclosed by the Company.

On behalf of the Board of Regeneus Ltd

==> picture [70 x 61] intentionally omitted <==

Helen Leung Company Secretary Regeneus Ltd

2 Paddington Street, Paddington, NSW 2021 Ph: 1300 995 098 • Fax: +61 2 9499 8020 • www.regeneus.com.au • ABN 13 127 035 358